Hsbc Holdings PLC Buys Shares of 43,615 HealthEquity, Inc. $HQY

Hsbc Holdings PLC bought a new position in HealthEquity, Inc. (NASDAQ:HQY) in the second quarter, HoldingsChannel reports. The institutional investor bought 43,615 shares of the company’s stock, valued at approximately $3,917,000.

Several other hedge funds have also recently modified their holdings of HQY. Acumen Wealth Advisors LLC bought a new position in shares of HealthEquity during the fourth quarter valued at $27,000. Aster Capital Management DIFC Ltd bought a new stake in HealthEquity in the 4th quarter worth about $28,000. Caitong International Asset Management Co. Ltd increased its holdings in HealthEquity by 1,723.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $28,000 after buying an additional 293 shares in the last quarter. Leonteq Securities AG raised its position in HealthEquity by 159.9% in the 1st quarter. Leonteq Securities AG now owns 382 shares of the company’s stock worth $32,000 after buying an additional 235 shares during the last quarter. Finally, Silvant Capital Management LLC purchased a new position in HealthEquity in the 2nd quarter worth about $35,000. Hedge funds and other institutional investors own 99.55% of the company’s stock.

HealthEquity News Summary

Here are the key news stories impacting HealthEquity this week:

• Positive Sentiment: HealthEquity exceeded expectations with adjusted earnings of $1.24 per share versus the $1.19 consensus, while revenue reached $350.7 million, slightly above estimates. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Profitability improved, with net income rising 10% to $65.6 million and net margin expanding to 19% from 18%. Adjusted EBITDA grew 11% to $167 million, while its margin increased to 48% from 46%. HealthEquity Second-Quarter Financial Results
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. Record HSA assets of $37.9 billion provide additional support for the company’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance
• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and raised its price target to $115. Another analysis indicated that HQY could be approximately 19% undervalued after the guidance increase, reinforcing the bullish interpretation of the earnings update. BTIG Research Rating HealthEquity Could Be Undervalued
• Neutral Sentiment: Fiscal 2027 revenue guidance of approximately $1.4 billion was broadly in line with expectations, so the guidance improvement was driven mainly by stronger anticipated earnings and margins.
• Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares valued at approximately $798,000, reducing his position by 10.9%. The sale was executed under a pre-arranged Rule 10b5-1 plan, which reduces its negative signaling value but could still attract investor attention. HealthEquity Director Stock Sale
• Negative Sentiment: HQY trades at a premium valuation of roughly 35 times earnings. After the recent advance toward its 52-week high, some investors may lock in gains, potentially tempering the stock’s reaction to otherwise favorable fundamentals.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Weiss Ratings raised shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, June 5th. Telsey Advisory Group set a $111.00 price objective on shares of HealthEquity in a report on Friday. Citizens Jmp increased their price objective on shares of HealthEquity from $110.00 to $111.00 and gave the company a “market outperform” rating in a research report on Monday, June 1st. Citigroup restated a “market outperform” rating on shares of HealthEquity in a report on Friday. Finally, Wall Street Zen raised shares of HealthEquity from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $110.93.

HealthEquity Stock Performance

Shares of NASDAQ HQY opened at $96.37 on Friday. The firm has a 50 day moving average of $98.16 and a 200 day moving average of $87.87. The company has a current ratio of 2.99, a quick ratio of 3.44 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $8.06 billion, a price-to-earnings ratio of 34.79, a price-to-earnings-growth ratio of 1.62 and a beta of 0.21. HealthEquity, Inc. has a 12-month low of $72.76 and a 12-month high of $107.62.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Thursday, August 27th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.05. The business had revenue of $350.73 million for the quarter, compared to the consensus estimate of $349.22 million. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The firm’s revenue was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. On average, research analysts anticipate that HealthEquity, Inc. will post 3.92 earnings per share for the current year.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Director Adrian T. Dillon sold 7,632 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total transaction of $798,383.52. Following the completion of the sale, the director owned 62,395 shares of the company’s stock, valued at approximately $6,527,140.95. The trade was a 10.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Henry Fiore sold 2,354 shares of the business’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $95.00, for a total value of $223,630.00. Following the sale, the executive vice president directly owned 52,244 shares of the company’s stock, valued at $4,963,180. This represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,456 shares of company stock valued at $1,256,664 over the last 90 days. 1.60% of the stock is currently owned by company insiders.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.